for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.OQ

Latest Trade

144.79USD

Change

0.00(-0.00%)

Volume

3,589,177

Today's Range

143.48

 - 

150.69

52 Week Range

18.30

 - 

189.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
144.79
Open
150.41
Volume
3,589,177
3M AVG Volume
467.52
Today's High
150.69
Today's Low
143.48
52 Week High
189.26
52 Week Low
18.30
Shares Out (MIL)
395.71
Market Cap (MIL)
59,423.79
Forward P/E
-102.97
Dividend (Yield %)
--

Next Event

Q4 2020 Moderna Inc Earnings Call

Latest Developments

More

Moderna Provides U.S. COVID-19 Vaccine Supply Update

Moderna Confirms Co Is Proposing Filling Vials With Additional Doses Of Vaccine - CNBC

Moderna Said To Seek FDA Clearance To Increase Doses Per Vial To Alleviate Manufacturing Bottleneck- CNBC

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resource Officer

Key Stats

2.56 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020(E)

0.5K
EPS (USD)

2018

-4.950

2019

-1.550

2020(E)

-1.548
Price To Earnings (TTM)
--
Price To Sales (TTM)
240.87
Price To Book (MRQ)
21.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.94
LT Debt To Equity (MRQ)
3.94
Return on Investment (TTM)
-25.87
Return on Equity (TTM)
-19.15

Latest News

Latest News

Moderna developing booster shot for new coronavirus variants, increases vaccine production target

Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus, and has raised its global COVID-19 vaccine production goal for this year by 100 million doses.

Moderna is developing booster shot for new coronavirus variants, increases vaccine production target

Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus and has raised its global COVID-19 vaccine production goal for this year by 100 million doses.

Israel's Netanyahu sets April target for reopening economy

Israel aims to reopen its economy by April 5 after having vaccinated all its eligible population and is in talks with vaccine makers Pfizer and Moderna to open facilities in the country, Prime Minister Benjamin Netanyahu said on Wednesday.

Takeda says first patient given Novavax COVID-19 vaccine in Japan clinical trial

Takeda Pharmaceutical Co said on Wednesday the first patient had been given Novavax Inc's COVID-19 vaccine candidate in a Japanese clinical trial.

South Africa says J&J, Pfizer, Moderna vaccines those for 'immediate use'

South Africa's health minister said on Tuesday that government advisers had organised COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson (J&J), Pfizer and Moderna shots.

South Africa says J&J, Pfizer, Moderna vaccines in group for "immediate use"

South Africa's health minister said on Tuesday that a committee advising the government had grouped COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson, Pfizer and Moderna shots.

First month of shots find no safety issues with Pfizer/BioNTech, Moderna vaccines: U.S. data

The two COVID-19 vaccines approved for use in the United States have reassuring safety profiles with no concerning new issues found in data collected from the first month of vaccinations, the U.S. Centers for Disease Control and Prevention (CDC) said on Friday.

Exclusive: Pfizer COVID-19 vaccine supply to the EU about 10 million doses short of plan -sources

Pfizer Inc has not yet delivered to the European Union about 10 million COVID-19 vaccine doses that were due in December, EU officials said, leaving it about one-third short of the supply it had expected from the U.S. drugmaker.

EU books 150 million extra Moderna COVID-19 vaccines for 2021, option for more in 2022

The European Commission said on Wednesday it had struck a deal for an extra 150 million doses of Moderna's COVID-19 vaccine this year, nearly doubling the number of shots secured from the U.S. biotech firm for 2021.

BRIEF-EU Set To Announce Fresh Vaccine Deal With Moderna - FT

* EU SET TO ANNOUNCE FRESH VACCINE DEAL WITH MODERNA - FT Source text: https://on.ft.com/3prZYAN Further company coverage:

Moderna says U.S. supply of its vaccine doses have lagged recently

Moderna Inc said on Tuesday the release of some of its COVID-19 vaccine doses to the U.S. government have lagged recently because of "short-term delays" in the final stages of production at its contractor Catalent Inc.

Moderna moves forward COVID-19 vaccine supply targets for U.S.

Moderna Inc said on Tuesday it was moving forward the supply targets for the second 100 million of its COVID-19 vaccine doses to the United States by a month to May end. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

Canada will get some doses of Pfizer's vaccine earlier than scheduled: PM Trudeau

Canada will receive some doses of Pfizer Inc's COVID-19 vaccine earlier than scheduled and is on track to inoculate the entire population by the end of September, Prime Minister Justin Trudeau said on Friday.

Fact check: Pfizer and Moderna do call their COVID-19 shot a ‘vaccine’

Posts have been circulating on social media claiming that only governments are calling the Pfizer-BioNTech and Moderna COVID-19 vaccines “vaccines”, and that the companies themselves call them “biological agents” and an “Operating System designed to program Humans.” This...

Qatar approves emergency use for Moderna covid-19 vaccine - Tweet

The Qatari health ministry issued an emergency use authorization on Wednesday for Moderna's COVID-19 vaccine, the ministry said in a tweet.

Bulgaria plans to order over 3 mln additional COVID vaccine doses

Bulgaria plans to order more than 3 million additional doses of COVID-19 vaccines from Pfizer-BioNTech and Moderna as a precaution against decreased deliveries from AstraZeneca, the government said on Wednesday.

Moderna to supply COVID-19 vaccine to Taiwan and Colombia

U.S. drugmaker Moderna Inc will supply its COVID-19 vaccine to the governments of Taiwan and Colombia, the company said, providing five million and 10 million doses respectively.

Moderna enters supply agreement for COVID-19 vaccine with Taiwan, Colombia

U.S. drugmaker Moderna Inc said on Tuesday it had entered supply agreements for its COVID-19 vaccine with the governments of Taiwan and Colombia for five million doses and 10 million doses, respectively.

UPDATE 2-S.Korea in talks with Moderna over $200 mln investment to build vaccine factory

South Korea and COVID-19 vaccine maker Moderna Inc are in discussions over a $200 million investment by the U.S. drugmaker to build a vaccine manufacturing factory in the country, a former government minister who was involved in the talks said.

Moderna in talks to invest around $200 mln in S.Korea to build factory - Asia Business Daily

Moderna Inc is in discussions with the South Korean government to potentially invest around $200 million in the country to build a factory, a local newspaper Asia Business Daily reported on Friday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up